IGF-1 (overview)
Fat LossIGF-1 / prescription (mecasermin)Experimental
Endogenous growth factor. Recombinant mecasermin (Increlex) is FDA-approved for severe primary IGF-1 deficiency. Research vials are unapproved. WADA S2.
For research use only.
Key Facts
- CAS
- 67763-96-6
- Molecular Weight (MW)
- 7649 Da
- Half-life
- ~10–16 hours (bound); minutes unbound
- Unit
- mcg
- Administration Route
- Subcutaneous
- Frequency
- —
- Last updated
- 8/23/2026
- Targets
- IGF-1 receptor
Overview
Endogenous growth factor. Recombinant mecasermin (Increlex) is FDA-approved for severe primary IGF-1 deficiency. Research vials are unapproved. WADA S2.
Protocol
- Dosage Range
- —
- Frequency
- —
- Cycle
- —
- Administration Route
- Subcutaneous
- Reconstitution Guide
- —
Science
Mechanism of Action
Activates IGF-1R tyrosine kinase to promote growth, protein synthesis, and hypoglycemia via insulin-receptor cross-talk at high levels.
Targets
IGF-1 receptor
Studies
- Mecasermin in severe IGF-1 deficiency— Journal/year not available
Benefits
Labeled severe primary IGFD therapy
Potential Side Effects
- Hypoglycemia
- Tonsillar hypertrophy
- Intracranial hypertension
References
- FDA label — IncrelexExternal link · Year —
- WADA Prohibited List 2026External link · Year —